Coeptis Therapeutics Holdings, Inc.
COEP
$9.75
$0.272.85%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -48.93% | -48.87% | -59.22% | -58.09% | -54.58% |
| Depreciation & Amortization | 0.00% | 100.00% | 100.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.25% | -10.22% | -28.56% | -37.15% | -37.25% |
| Operating Income | 47.25% | 10.22% | 28.56% | 37.15% | 37.25% |
| Income Before Tax | 43.18% | 18.27% | 38.11% | 43.40% | 45.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.18% | 18.27% | 38.11% | 43.40% | 45.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.18% | 18.27% | 38.11% | 43.40% | 45.41% |
| EBIT | 47.25% | 10.22% | 28.56% | 37.15% | 37.25% |
| EBITDA | 49.58% | 10.79% | 29.75% | 38.27% | 38.02% |
| EPS Basic | 65.89% | 54.30% | 66.48% | 68.77% | 67.73% |
| Normalized Basic EPS | 66.43% | 54.80% | 66.74% | 65.68% | 64.00% |
| EPS Diluted | 65.89% | 54.30% | 66.48% | 68.77% | 67.73% |
| Normalized Diluted EPS | 66.43% | 54.80% | 66.74% | 65.68% | 64.00% |
| Average Basic Shares Outstanding | 69.45% | 81.98% | 82.33% | 79.14% | 68.69% |
| Average Diluted Shares Outstanding | 69.45% | 81.98% | 82.33% | 79.14% | 68.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
